MA53902A - Dérivés de flavagline pour inhiber l'activation d'un oncogène kras - Google Patents
Dérivés de flavagline pour inhiber l'activation d'un oncogène krasInfo
- Publication number
- MA53902A MA53902A MA053902A MA53902A MA53902A MA 53902 A MA53902 A MA 53902A MA 053902 A MA053902 A MA 053902A MA 53902 A MA53902 A MA 53902A MA 53902 A MA53902 A MA 53902A
- Authority
- MA
- Morocco
- Prior art keywords
- oncogene activation
- inhibiting kras
- kras oncogene
- flavagline derivatives
- flavagline
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000006508 oncogene activation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200610.6A EP3639820A1 (fr) | 2018-10-16 | 2018-10-16 | Dérivés de flavagline pour inhiber l'activation de l'oncogène kras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53902A true MA53902A (fr) | 2021-08-25 |
Family
ID=63878357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053902A MA53902A (fr) | 2018-10-16 | 2019-10-15 | Dérivés de flavagline pour inhiber l'activation d'un oncogène kras |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230165829A1 (fr) |
| EP (2) | EP3639820A1 (fr) |
| JP (1) | JP2022513367A (fr) |
| KR (1) | KR20210113162A (fr) |
| CN (1) | CN112867488A (fr) |
| AU (2) | AU2019362576B2 (fr) |
| BR (1) | BR112021007142A2 (fr) |
| CA (1) | CA3116603A1 (fr) |
| EA (1) | EA202191040A1 (fr) |
| IL (1) | IL282301A (fr) |
| MA (1) | MA53902A (fr) |
| MX (1) | MX2021004380A (fr) |
| SG (1) | SG11202103885YA (fr) |
| WO (1) | WO2020078975A1 (fr) |
| ZA (1) | ZA202103150B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112359060B (zh) * | 2020-11-11 | 2022-12-23 | 吉林医药学院 | 含有靶向突变型kras融合基因的重组载体、融合蛋白及蛋白质复合物及其构建方法和应用 |
| EP4395775A1 (fr) | 2021-09-01 | 2024-07-10 | KHR Biotec GmbH | Dérivés de cyclopenta[4,5]furo[3,2-c]pyridine en tant qu'inhibiteurs de ras destinés à être utilisés dans le traitement de maladies hyperprolifératives ou de troubles génétiques |
| CN118234715A (zh) | 2021-09-01 | 2024-06-21 | Khr生物技术有限公司 | 新ras抑制剂 |
| WO2024056619A1 (fr) | 2022-09-13 | 2024-03-21 | KHR Biotec GmbH | Dérivés de 1h-cyclopenta[b]benzofurane pour la prévention et le traitement de maladies virales |
| CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
| WO2024175659A1 (fr) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | 3ah-cyclopenta[b]benzofuran-3a-yl utilisé en tant qu'inhibiteurs de ras |
| WO2024175662A1 (fr) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | Dérivés de la flavagline en tant qu'inhibiteurs du système rénine-angiotensine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967360A (ja) * | 1995-08-28 | 1997-03-11 | Terumo Corp | 癌遺伝子機能抑制剤 |
| DE102004024504A1 (de) * | 2004-05-18 | 2006-02-16 | Bayer Healthcare Ag | Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung |
| EP2189453A1 (fr) * | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Dérivés de rocaglaol en tant qu'agents cardioprotecteurs |
| EP2457907A1 (fr) * | 2010-11-16 | 2012-05-30 | Université de Strasbourg | Dérivés de flavagline en tant qu'agents neuroprotecteurs |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| EP3356351A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
-
2018
- 2018-10-16 EP EP18200610.6A patent/EP3639820A1/fr not_active Withdrawn
-
2019
- 2019-10-15 MA MA053902A patent/MA53902A/fr unknown
- 2019-10-15 JP JP2021546459A patent/JP2022513367A/ja active Pending
- 2019-10-15 US US17/285,583 patent/US20230165829A1/en active Pending
- 2019-10-15 EA EA202191040A patent/EA202191040A1/ru unknown
- 2019-10-15 CN CN201980068403.0A patent/CN112867488A/zh active Pending
- 2019-10-15 AU AU2019362576A patent/AU2019362576B2/en active Active
- 2019-10-15 BR BR112021007142-3A patent/BR112021007142A2/pt unknown
- 2019-10-15 WO PCT/EP2019/077916 patent/WO2020078975A1/fr active Application Filing
- 2019-10-15 MX MX2021004380A patent/MX2021004380A/es unknown
- 2019-10-15 EP EP19786977.9A patent/EP3866780A1/fr active Pending
- 2019-10-15 SG SG11202103885YA patent/SG11202103885YA/en unknown
- 2019-10-15 CA CA3116603A patent/CA3116603A1/fr active Pending
- 2019-10-15 KR KR1020217014700A patent/KR20210113162A/ko not_active Application Discontinuation
-
2021
- 2021-04-13 IL IL282301A patent/IL282301A/en unknown
- 2021-05-10 ZA ZA2021/03150A patent/ZA202103150B/en unknown
- 2021-10-12 AU AU2021107577A patent/AU2021107577A4/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3116603A1 (fr) | 2020-04-23 |
| AU2019362576A1 (en) | 2021-06-03 |
| AU2021107577A4 (en) | 2022-01-06 |
| EP3866780A1 (fr) | 2021-08-25 |
| JP2022513367A (ja) | 2022-02-07 |
| EP3639820A1 (fr) | 2020-04-22 |
| WO2020078975A1 (fr) | 2020-04-23 |
| SG11202103885YA (en) | 2021-05-28 |
| IL282301A (en) | 2021-05-31 |
| CN112867488A (zh) | 2021-05-28 |
| BR112021007142A2 (pt) | 2021-07-20 |
| US20230165829A1 (en) | 2023-06-01 |
| AU2019362576B2 (en) | 2023-07-27 |
| KR20210113162A (ko) | 2021-09-15 |
| MX2021004380A (es) | 2021-09-08 |
| ZA202103150B (en) | 2022-10-26 |
| EA202191040A1 (ru) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53902A (fr) | Dérivés de flavagline pour inhiber l'activation d'un oncogène kras | |
| MA54327A (fr) | Inhibiteurs de kras g12c | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| SG11202104326TA (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| SG11202100130QA (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
| IL279714A (en) | Heteroaryl compounds for the treatment of Huntington's disease | |
| MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA51897A (fr) | Procédés d'utilisation de dérivés de benzotriazole trisubstitués | |
| MA49127A (fr) | Dérivés d'indole n-substitués | |
| GB201819126D0 (en) | Inhibitor compounds | |
| MA52891A (fr) | Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase | |
| MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| MA51284A (fr) | Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho | |
| MA51285A (fr) | Dérivés d'azaindole comme inhibiteurs de rho-kinase | |
| MA51283A (fr) | Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho | |
| MA52934A (fr) | Composés inhibiteurs de l'oga | |
| MA52937A (fr) | Composés inhibiteurs d'oga |